Unique high-affinity synthetic μ-opioid receptor agonists with central- and systemic-mediated analgesia

Journal of Medicinal Chemistry

Volumn 46, Issue 15, 2003, Pages 3201-3209

  Okada, Yoshio ^a   Tsuda, Yuko ^a   Fujita, Yoshio ^a   Yokoi, Toshio ^a   Sasaki, Yusuke ^b   Ambo, Akihiro ^b   Konishi, Ryoji ^c   Nagata, Mitsuhiro ^c   Salvadori, Severo ^d   Jinsmaa, Yunden ^e   Bryant, Sharon D ^e   Lazarus, Lawrence H ^e  

^a KOBE GAKUIN UNIVERSITY   (Japan)

^b TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^c Teikoku Seiyaku Co Ltd   (Japan)

^d UNIVERSITY OF FERRARA   (Italy)

^e NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; AROMATIC COMPOUND; ETHYLENE DERIVATIVE; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NALOXONE; TYROSINE DERIVATIVE;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; IC 50; IN VIVO STUDY; MOLECULAR MODEL; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE;

ANALGESICS; ANIMALS; BRAIN; ELECTRIC STIMULATION; GUINEA PIGS; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SUBCUTANEOUS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MODELS, MOLECULAR; MOLECULAR MIMICRY; MUSCLE CONTRACTION; MUSCLE, SKELETAL; NARCOTICS; RADIOLIGAND ASSAY; RATS; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP; TYROSINE; VAS DEFERENS;

EID: 0038155285     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020459z     Document Type: Article

References (41)

1. 2, negative log of the molar concentration required to double the agonist concentration to achieve the original response; Ph, phenyl; PyBOP, benzoltriazol-1-yloxy-trispyrrolidinophosphonium hexafluorphosphate; TEA, triethylamine; TFA, trifluoroacetic acid; TLC, thin-layer chromatography; Z, benzyloxycarbonyl.
2. Vaccarino, A. L.; Kastin, A. J. Endogenous opiates: 1999. Peptides 2000, 21, 1975-2034.
3. Lazarus, L. H.; Attila, M. The toad, ugly and venomous, wears yet a precious jewel in his skin. Prog. Neurobiol. 1993, 41, 473-507.
4. Meunier, J.; Mollereau, C.; Toll, L.; Suaudeau, C.; Molsand, C.; Alvinerie, P.; Butour, J.; Guillemot, B.; Mazargull, H.; Vassart, G.; Parmentier, M.; Costentin, J. Isolation and structure of the endogenous agonist of opioid receptor-like ORL receptor. Nature 1995, 377, 532-535.
5. Chandrakumar, N. S.; Yonan, P. K.; Stapelfeld, A.; Savage, M.; Rorbacher, E.; Contreras, P. C.; Hammond, D. Preparation and opioid activity of analogues of the analgesic dipeptide 2,6-dimethyl-L-tyrosyl-N-(3-phenylpropyl)-D-alaninamide. J. Med. Chem. 1992, 35, 223-233.
6. 5]enkephalin. J. Med. Chem. 1992, 35, 684-687.
7. Salvadori, S.; Attila, M.; Balboni, G.; Bianchi, C.; Bryant, S. D.; Crescenzi, O.; Guerrini, R.; Picone, D.; Tancredi, T.; Temussi, P. A.; Lazarus, L. H. δ Opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides. Mol. Med. 1995, 1, 678-689.
8. 1]deltorphin B. Eur. J. Pharmacol. 1996, 302, 37-42.
9. Sasaki, Y.; Suto, T.; Ambo, A.; Ouchi, H.; Yamamoto, Y. Biological properties of opioid peptides replacing Tyr at position 1 by 2,6-dimethyl-Tyr. Chem. Pharm. Bull. 1999, 47, 1506-1507.
10. Schiller, P. W.; Nguyen, T. M.-D.; Berezowska, I.; Dupuis, S.; Weltrowska, G.; Chung, N. N.; Lemieux, C. Synthesis and in vitro opioid activity profiles of DALDA analogues. Eur. J. Med. Chem. 2000, 35, 895-901.
11. Fujita, Y.; Takahashi, M.; Yokoi, T.; Tsuda, Y.; Lazarus, L. H.; Bryant, S. D.; Anbo, A.; Sasaki, Y.; Okada, Y. Development of endomorphin derivatives with dual functions and studies on their three-dimensional structure. In Peptides: The Wave of the Future; Lebl, M., Houghten, R. A., Eds.; American Peptide Society: San Diego, CA, 2001; pp 616-617.
12. Schiller, P. W.; Nguyen, T. M.-D.; Weltrowska, G.; Wilkes, B. C.; Marsden, J.; Lemieux, C.; Chung, N. N. Differential stereo-chemical requirements of μ vs. δ opioid receptors for ligand binding and signal transduction: development of a class of potent and highly δ-selective peptide antagonists. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 11871-11875.
13. Salvadori, S.; Guerrini, R.; Balboni, G.; Bianchi, C.; Bryant, S. D.; Cooper, P. S.; Lazarus, L. H. Further studies on the Dmt-Tic pharmacophore: Hydrophobic substituents at the C-terminus endows δ antagonists to manifest μ agonism or μ antagonism. J. Med. Chem. 1999, 42, 5010-5019.
14. Balboni, G.; Guerrini, R.; Salvadori, S.; Bianchi, C.; Rizzi, D.; Bryant, S. D.; Lazarus, L. H. Evaluation of the Dmt-Tic pharmacophore: conversion of a potent δ-opioid receptor antagonist into a potent δ-agonist and ligands with mixed properties. J. Med. Chem. 2002, 45, 713-720.
15. Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Gionnini, Y.; Yunden, J.; Bryant, S. D.; Lazarus, L. H. New potent δ-opioid agonists based on the Dmt-Tic pharmacophore. J. Med. Chem. 2002, 45, 5556-5563.
16. Schwyzer, R. ACTH: A short introductory review. Ann. N. Y. Acad. Sci. 1977, 297, 3-26.
17. Schwyzer, R. Molecular mechanism of opioid selection. Biochemistry 1986, 25, 6335-6342.
18. Portoghese, P. S. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharmacol. Sci. 1989, 10, 230-235.
19. Portoghese, P.; Takemori, A. E.; Sultana, M. Design of peptidomimetic δ opioid receptor antagonists using the message-address concept. J. Med. Chem. 1990, 33, 1714-1720.
20. Portoghese, P. S.; Nagase, H.; MaloneyHuss, K. E.; Lin, C.-E.; Takemori, A. Role of spacer and address components in peptidomimetic δ opioid receptor antagonist related to naltrindole. J. Med. Chem. 1991, 34, 1715-1720.
21. Zadina, J. E.; Hackler, L.; Ge, L.-J.; Kastin, A. J. A potent and selective endogenous agonist for the μ-opiate receptor. Nature 1996, 386, 499-501.
22. 2 opiate receptors. Neurosci. Lett. 1996, 215, 65-69.
23. Okada, Y.; Fukumizu, A.; Takahasi, M.; Yamazaki, J.; Yokoi, T.; Tsuda, Y.; Bryant, S. D.; Lazarus, L. H. Amino acids and peptides. LVI. Synthesis of pyrazinone ring-containing opioid mimetics and examination of their opioid receptor binding activity. Tetrahedron 1999, 55, 14391-14406.
24. Okada, Y.; Fukumizu, A.; Takahashi, M.; Yokoi, T.; Tsuda, Y.; Bryant, S. D.; Lazarus, L. H. Synthesis of pyrazinone ring-containing opioid mimetics and examination of their opioid receptor-binding activity. Chem. Pharm. Bull. 1999, 47, 1193-1195.
25. Callahan, J. F.; Ashton-Shue, D.; Bryant, H. G.; Bryant, W. M.; Heckman, G. D.; Kinter, L. B.; McDonald, J. E.; Moore, M. L.; Schmidt, D. B.; Silvestri, J. S.; Stassen, F. L.; Sulat, L.; Yim, N. C. F.; Huffman, W. F. Structure-activity relationships of novel vasopressin antagonists containing C-terminal diaminoalkanes and (aminoalkyl)guanidines. J. Med. Chem. 1989, 32, 391-396.
26. Schiller, P. W.; Weltroska, G.; Berezowska, I.; Nguyen, T. M.-D.; Wilkes, B. C.; Lemieux, C.; Chung, N. N. The TIPP opioid peptide family: development of δ antagonists, δ agonists, and mixed μ agonists/δ antagonists. Biopolymers 1999, 51, 411-425.
27. Lazarus, L. H.; Bryant, S. D.; Cooper, P. S.; Salvadori, S. What peptides these deltorphins be. Prog. Neurobiol. 1999, 57, 377-420.
28. Melchiorri, P.; Negri, L. The dermorphin peptide family. Gen. Pharmacol. 1996, 27, 1099-1107.
29. Hughes, J.; Smith, T. W.; Kosterlitz, H. W.; Fothergill, L. A.; Morgan, B. A.; Morris, H. R. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 1975, 258, 577-580.
30. Roques, B. P.; Gacel, G.; Fournie-Zaluski, M.-C.; Senault, B.; Lecomte, J.-M. Demonstration of the crucial role of the phenyl-alanine moiety in enkephalin analogues for differential recognition of the μ- and δ-receptors. Eur. J. Pharmacol. 1979, 60, 109-110.
31. Okada, Y.; Tsukatani, M.; Taguchi, H.; Yokoi, T.; Bryant, S. D.; Lazarus, L. H. Design and synthesis of opioid mimetics containing pyrazinone ring and examination of their opioid receptor binding activity. In Peptides: Frontiers of Peptide Science; Tam, J. P., Kaumaya, P. T. P., Eds.; Kluwer Academic: Dodrecht, The Netherlands, 1997; pp 660-661.
32. Goodman, M.; Ro, S.; Osapay, G.; Yamazaki, T.; Polinsky, A. The molecular basis of opioid potency and selectivity: morphiceptins, dermorphins, deltorphins, and enkephalins. NIDA Res. Monogr. 1993, 143, 195-209.
33. (a) Bryant, S. D.; Salvadori, S.; Attila, M.; Lazarus, L. H. Topographical conformations of the deltorphins predicate δ opioid receptor affinity. J. Am. Chem. Soc. 1993, 115, 8503-8504.
34. (b) Bryant, S. D.; Balboni, G.; Guerrini, R.; Salvadori, S.; Tomatis, R.; Lazarus, L. H. Opioid diketopiperazines: refinement of the δ opioid antagonist pharmacophore. Biol. Chem. 1997, 378, 107-114.
35. (c) Bryant, S. D.; Salvadori, S.; Okada, Y.; Takahshi, M.; Sasaki, Y.; Lazarus, L. H. Computational chemistry and opioidmimetics: Receptor ligand interaction of three classes of biologically potent peptides. In Peptides 2000; Martinez, J., Fehrentz, J.-A., Eds.; Editions EDK: Paris, 2001; pp 407-408.
36. Bryant, S. D.; George, C.; Flippen-Anderson, J.; Salvadori, S.; Balboni, G.; Guerrini, R.; Lazarus, L. H. Solid-state structure of analogues containing the Dmt-Tic pharmacophore. J. Med. Chem. 2002, 45, 5506-5513.
37. 2[ψ] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. J. Med. Chem. 1999, 42, 3520-3526.
38. Shimohigashi, Y.; Costa, T.; Mastuura, S.; Chen, H.-C.; Rodbard, D. Dimeric enkephalins display enhanced affinity and selectivity for the delta opioid receptor. Mol. Pharmacol. 1982, 21, 558-563.
39. Lazarus, L. H.; Guglietta, A.; Wilson, W. E.; Irons, B. J.; de Castiglione, R. Dimeric dermorphin analogues as μ-receptor probes on rat brain membranes. Correlation between central μ-receptor potency and suppression of gastric acid secretion. J. Biol. Chem. 1989, 264, 354-362.
40. Dygos, J. H.; Yonan, E. E.; Scaros, M. G.; Goodmonson, O. J.; Getman, D. P.; Periana, R. A.; Beck, G. R. A convenient asymmetric synthesis of the unnatural amino acid 2,6-dimethyl-L-tyrosine. Synthesis 1992, 8, 741-743.
41. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.